Humanigen, Inc. (HGEN) financial statements (2021 and earlier)

Company profile

Business Address 533 AIRPORT BLVD.
BURLINGAME, CA 94010
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:011384177
Cash and cash equivalents011381154
Short-term investments     3023
Other undisclosed cash, cash equivalents, and short-term investments00     
Restricted cash and investments00 00  
Receivables  1   0
Other undisclosed current assets00(1)2221
Total current assets:0125104278
Noncurrent Assets
Property, plant and equipment (0)00000
Restricted cash and investments000000 
Other noncurrent assets    0  
Other undisclosed noncurrent assets 0   01
Total noncurrent assets:0000111
TOTAL ASSETS:1125114379
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8675 34
Accounts payable5334 23
Employee-related liabilities3331 11
Debt11   113
Due to related parties2      
Deferred revenue and credits183 00
Other undisclosed current liabilities21   44
Total current liabilities:148258 1811
Noncurrent Liabilities
Long-term debt and lease obligation1 11  7
Long-term debt, excluding current maturities1 11  7
Liabilities, other than long-term debt     0 
Deferred revenue and credits   0 
Other undisclosed noncurrent liabilities 1     
Total noncurrent liabilities:1111 07
Other undisclosed liabilities    5  
Total liabilities:15926951818
Stockholders' equity
Stockholders' equity attributable to parent(14)(8)(24)(4)62561
Common stock0000000
Additional paid in capital270266238236219203201
Accumulated other comprehensive income (loss)     (0)0
Accumulated deficit(285)(275)(263)(241)(214)(178)(140)
Total stockholders' equity:(14)(8)(24)(4)62561
TOTAL LIABILITIES AND EQUITY:1125114379

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Gross profit:      0
Operating expenses(9)(11)(19)(19)(34)(37)(41)
Other undisclosed operating loss      (0)
Operating loss:(9)(11)(19)(19)(34)(37)(41)
Nonoperating income (expense)(0)000(0)(1)(0)
Investment income, nonoperating    0(0)(0)
Other nonoperating income (expense)(0)000(0)(0)(0)
Interest and debt expense(1)(1)(3)(0)(1)(1)(1)
Net loss:(10)(12)(22)(19)(35)(38)(42)
Other undisclosed net income (loss) attributable to parent (0)(0)(8) 00
Net loss available to common stockholders, diluted:(10)(12)(22)(27)(35)(38)(42)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(10)(12)(22)(19)(35)(38)(42)
Comprehensive loss:(10)(12)(22)(19)(35)(38)(42)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (0)(0)(8)000
Comprehensive loss, net of tax, attributable to parent:(10)(12)(22)(27)(35)(38)(42)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: